| 引用本文:王荣华，马良赟，廖泽飞，张乐，王耿杰.黄芪注射液对中晚期NSCLC患者化疗后骨髓系统和肿瘤标志物的影响[J].世界中医药,2018,(11):. |
|
| 黄芪注射液对中晚期NSCLC患者化疗后骨髓系统和肿瘤标志物的影响 |
| Effects of Huangqi Injection on Bone Marrow System and Tumor Markers in Patients with Middle-advanced Stage Non-small-cell Lung Cancer after Chemotherapy |
| 投稿时间：2018-09-10 |
| DOI：10.3969/j.issn.1673-7202.2018.11.033 |
| 中文关键词: 中晚期非小细胞肺癌 化疗 黄芪注射液 骨髓系统 肿瘤标志物 |
| English Keywords:Middle-advanced stage non-small-cell lung cancer Chemotherapy Huangqi Injection Bone marrow system Tumor markers |
| 基金项目:泉州市科技计划项目(2012z66) |
|
| 摘要点击次数: 974 |
| 全文下载次数: 683 |
| 中文摘要: |
| 目的:探讨黄芪注射液对中晚期非小细胞肺癌(NSCLC)患者化疗后骨髓系统和肿瘤标志物的影响。方法:选取2016年2月至2017年4月中国人民解放军第180医院收治的中晚期NSCLC患者75例,按随机数字表法随机分为对照组(n=37)和观察组(n=38)。2组患者均进行化疗,21 d为1个周期,共化疗4个周期,观察组在每个化疗周期的前15 d进行黄芪注射液静脉滴注,1次/d,共治疗4个周期。检测2组患者化疗前后全血T细胞亚群变化、骨髓抑制情况、血清肿瘤标志物水平;化疗4个周期后统计2组临床疗效。结果:与化疗前比,化疗1~4个周期后2组全血CD3+、CD4+比例及观察组CD4+/CD8+呈先降低后升高趋势(P<0.05或P<0.01),且化疗2、4个周期后观察组显著高于对照组(P<0.01);2组全血CD8+较化疗前呈先升高后降低的趋势,且化疗2、4个周期后观察组显著低于对照组(P<0.01);与化疗前比,化疗4个周期后2组全血白细胞计数、血小板计数、血红蛋白水平及中性粒细胞计数显著降低(P<0.01),且对照组显著低于观察组(P<0.01);与化疗前比,化疗4个周期后2组血清CEA、CA-50、CYFRA21-1水平显著降低,且观察组显著低于对照组(P<0.01);化疗4个周期后观察组ORR为71.05%,显著高于对照组的40.54%(P<0.05)。结论:黄芪注射液可显著改善中晚期NSCLC患者化疗后免疫状态及骨髓系统,降低其肿瘤标志物水平,提高化疗疗效。 |
| English Summary: |
| To explore the effects of Huangqi Injection on bone marrow system and tumor markers in patients with middle-advanced stage non-small-cell lung cancer (NSCLC) after chemotherapy.Methods:A total of 75 patients with middle-advanced stage NSCLC admitted to The 180th Hospital of PLA from February 2016 to April 2017 were selected and divided randomly into control group (n=37) and observation group (n=38) according to random number table method.The patients of 2 groups received chemotherapy for four 21-day courses.The observation group was given intravenous injection of Huangqi Injection at the first 15 days of each chemotherapy course (1 time/d)，and it was continuously treated for 4 courses.The whole blood T cell subsets，bone marrow inhibition and serum tumor markers levels were detected before and after chemotherapy; the clinical efficacy in 2 groups were statistically analyzed after 4 courses of chemotherapy.Results:Compared with before chemotherapy，the whole blood CD3+，CD4+ ratio in 2 groups and CD4+/CD8+ in observation group showed a trend of decreasing first and then increasing after 1-4 courses of chemotherapy (P<0.05 or P<0.01); and observation group was significantly higher than control group after 2-4 courses of chemotherapy (P<0.01); the whole blood CD8+ ratio in the two groups showed a trend of increasing first and then decreasing (P<0.01)，and observation group was significantly lower than control group after 2-4 courses of chemotherapy (P<0.01).Compared with before chemotherapy，the serum leukocyte count，platelet count，hemoglobin level and neutrophil count in 2 groups after 4 courses of chemotherapy significantly decreased (P<0.05 or P<0.01)，and observation group was significantly lower than control group (P<0.01).Compared with before chemotherapy，serum CEA，CA-50 and CYFRA21-1 levels in 2 groups after 4 courses of chemotherapy significantly decreased，and observation group was significantly lower than control group (P<0.01); ORR in observation group was 71.05% after 4 courses of chemotherapy，which was significantly higher than that 40.54% in control group (P<0.05).Conclusion:Huangqi Injection can significantly improve the immune status and bone marrow system of patients with middle-advanced stage NSCLC after chemotherapy，reduce the levels of tumor markers，and improve the efficacy of chemotherapy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
